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Abstract
Cisplatin belongs to the most widely used cytostatic drugs.
The determination of the presence of the DNA-cisplatin
adducts may not only signal the guanine-rich regions but
also monitor the interaction reaction between DNA and the
drug in terms of speed of interaction.
In this work, the combined advantages of magnetic
particles-based isolation/purification with fluorescent
properties of quantum dots (QDs) and antibodies targeted
on specific recognition of DNA-cisplatin adducts are
demonstrated. The formation of a complex between
magnetic particles with surface modified by anti-dsDNA
antibody, cisplatin-modified DNA and QDs labelled anti-
cisplatin-modified DNA antibody was suggested and
optimized.
Keywords Anti-DNA Antibodies, Cisplatin, Magnetic
Separation, Sandwich Analysis
1. Introduction
The method of magnetic separation can be employed in the
analysis of many different compounds, from ions [1-3] and
amino acids [4-6] through nucleic acids [7-9] and proteins
[10-12] to virions [13-15] or even whole bacterial cells
[16-18]. Spherical structures of nanometric or micrometric
size with paramagnetic or superparamagnetic properties
are used in magnetic separation [6].
The surface of magnetic particles (MPs) is modified either
with a charged layer for electrostatic adsorption or ligands
for specific bond with biomolecules [19]. One of the
frequently used ligands is protein G, naturally occurring in
Streptococcal bacteria. It is a cell surface protein with the
ability to bind immunoglobulins via their Fc region. Thus,
the antibodies retain their immunoprecipitating activity
even after binding to MPs [20]. A wide range of both
monoclonal and polyclonal antibodies can be bound to
protein G, including human, mouse, rat, bovine, goat or
rabbit [21].
The antibodies bound on MPs can subsequently be used in
an ELISA-like method for identification or analysis of a
desired antigen [12].  The secondary antibody for  sand‐
wich ELISA can be labelled according to standard proto‐
cols either with enzyme or fluorescent nanoparticles [22].
Use of micro- and nanoparticles in immunoassays allows
shortened analysis time with minimal sample requirement
and higher sensitivity compared to common formats [23, 24].
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In this work, we employed the sandwich ELISA-like
method using magnetic separation for selective analysis of
DNA modified with the cytotoxic drug cisplatin. The
affinity of anti-dsDNA primary and anti-cisplatin-modi‐
fied DNA secondary antibodies to DNA was confirmed
with a dot blot technique. The secondary antibody was
labelled with QDs for fluorescent detection of DNA.
2. Materials and Methods
2.1 Chemicals
All chemicals of ACS purity were obtained from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise stated.
Deionized water underwent demineralization by reverse
osmosis using the instrument Aqua Osmotic 02 (Aqua
Osmotic, Tisnov, Czech Republic), followed by further
purification using Millipore RG (Millipore, Billerica, MA,
USA) Milli-Q water. The pH was measured using a WTW
inoLab pH meter (Weilheim, Germany).
2.2 Amplification of DNA fragments by polymerase chain
reaction
DNA isolated from bacteriophage λ (48 502 bp) and a Taq
PCR kit were purchased from New England Biolabs
(Ipswich, MA, USA). Primers were synthesized by Sigma-
Aldrich (St. Louis, MO, USA) and their sequence was 5´-
CCTGCTCTGCCGCTTCACGC-3´ for forward primer and
5´-TCCGGATAAAAACGTCGATGACATTTGC-3´ for
reverse primer. The volume of reaction mixture was 50μL
and it was composed of 5μl of 10× standard Taq reaction
buffer; 1μL of 1mM deoxynucleotide solution; 1μL of each
10μM primer; 0.25μL of Taq DNA polymerase; 40.75μL of
water (sterile) and 1μL of 0.5μg/μL DNA. PCR took place
in Mastercycler ep realplex4 S (Eppendorf, Hamburg,
Germany) and the cycling conditions were as follows:
denaturation for 120 s at 95 °C; 30 cycles of denaturation for
15 s at 95 °C, annealing for 15 s at 64 °C and elongation for
45 s at 72 °C with a final elongation for 5 min at 72 °C.
Obtained DNA fragments (498 bp) were purified using the
MinElute PCR Purification Kit (Qiagen, Hilden, Germany).
DNA concentration was determined spectrophotometri‐
cally (Analytic Jena, Jena, Germany).
2.3 Cisplatin interactions with DNA
DNA fragments solution (final concentration of 40.62nM)
was mixed with cisplatin (final concentration of 0.13, 0.26,
0.52, 1.04, 2.08, 4.17, 8.33 and 16.66μM) in the environment
of 10mM NaClO4. Solutions of DNA with drugs were
incubated for 24 hours at 37 °C.
2.4 Dot blot assay
2μL of the DNA samples (0.1 – 162.5nM DNA fragment or
40.6nM DNA fragment with 0.1 – 16.7μM cisplatin) were
immobilized on a Zeta Probe membrane (Bio-Rad, Her‐
cules, CA, USA) and dried at 37 °C in an incubator Galaxy
14S (Eppendorf, Hamburg, Germany). The membrane was
blocked for 30 min during rotation at 40 RPM (Multi RS-60,
Biosan, Latvia) in a blocking buffer containing 1% milk
powder in PBS (137mM NaCl, 2.7mM KCl, 1.4mM
NaH2PO4 and 4.3mM Na2HPO4, pH 7.4). The solution was
replaced by an antibody dilution buffer (1mg/mL bovine
serum albumin in PBS) with the primary antibodies (anti-
dsDNA antibody or anti-cisplatin modified DNA antibody,
Abcam, Cambridge, England). The primary antibodies
were diluted by buffer in the ratio 1:1000. The membrane
was incubated with antibodies for 60 minutes at room
temperature during rotation and then washed with PBS
with 0.05% Tween 20 (PBS-T). The secondary polyclonal
rabbit anti-mouse antibodies labelled with horseradish
peroxidase (Dako, Denmark) in dilution of 1:1500 in
dilution buffer were added to the membrane and incubated
for 60 minutes during rotation. Visualization in chromo‐
genic substrate followed after washing with PBS-T. The
membrane was immersed in the solution composed of
substrate buffer (0.5M acetate buffer, pH 5.4), 0.4mg/mL 3-
amino-9-ethylcarbazole and hydrogen peroxide in the ratio
1000:10:1. The assay was performed according to [25].
The mean intensity of the colour was quantified using the
Carestream Molecular Software (Rochester, NY, USA) in
each spot and the colour of the background was deducted.
2.5 CdTe quantum dots preparation
Under  magnetic  stirring  1mL  of  aqueous  solution  of
Cd(OAc)2  (5.32mg/mL)  was  added to  7.6mL of  Milli-Q
water. Then 1mg of HWRGWVC heptapeptide (abbrevi‐
ated HWR peptide) and 50μL of 60mg/mL mercaptosuc‐
cinic acid were added. Preparation proceeded by adding
90μL  of  1M  NH3  and  150μl  of  4.43mg/mL  Na2TeO3.
Reductions of samples were conducted by adding 4mg of
NaBH4. Solutions were closed in vials and added into the
Multiwave 3000Microwave Reaction System (Anton Paar,
Graz, Austria) for 20 min at 110 °C and power of 300 W.
To  remove  the  excess  HWR  peptide,  the  QDs  were
filtered  by  the  Amicon  Ultra  3K  device  (Millipore,
Billerica, MA, USA).
2.6 The magnetic particles-based immunoassay
The magnetic microparticles Dynabeads Protein G (Life
Technologies,  Carlsbadt,  CA,  USA)  and  magnetic
separation  rack  MagnaRack  (Life  Technologies,  Carls‐
bad,  CA,  USA)  were  used  for  immunoseparation.  The
anti-dsDNA  antibodies’  immobilization  on  the  MPs’
surface  was  done  according  to  the  manufacturer's
recommendations.  The  storage  solution  was  removed
from the 50μL (1.5mg) of resuspended MPs in a tube on
the  magnetic  rack.  10μg  of  anti-dsDNA  antibodies  in
200μL of  PBS-T was  added to  the  MPs.  In  the  case  of
binding capacity optimization the 0.25, 0.5, 1, 2, 5, 8, 10
and 15μg of anti-dsDNA antibodies were added to 1mg
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of MPs. The MPs were incubated with antibodies for 30
min during rotation at  40 RPM and room temperature.
After  that,  the  tube  with  the  MPs  was  placed  on  the
magnetic  rack,  the  supernatant  was  removed  and  the
MPs-antibodies complex was washed by 200μL of PBS-
T. The MPs were resuspended in 200μl of PBS-T and 50μL
(0.38mg) of this mixture was placed on the magnetic rack.
The supernatant was removed and 10μL of DNA sample
in 20μL of Tris-HCl (pH 8) with 0.1M NaCl was added.
The  DNA  samples  were  162.48nM  PCR  fragment  or
40.62nM PCR fragment with 8.3 and 16.7μM cisplatin. The
incubation with the MPs-antibodies complex was carried
out  for  60  min  during  rotation  at  40  RPM  and  room
temperature.
In the case of testing DNA binding to the MPs, the MPs
were twice washed by 200μL of Tris-HCl (pH 8) with 0.1M
NaCl. After the removal of the supernatant the washed MPs
were incubated with 10μL of acetate buffer (0.2M sodium
acetate and 1M NaCl, pH 4) for 60 min during rotation at
40 RPM and room temperature. Then the tube with MPs
was placed on magnetic rack and the eluted DNA was
removed to a new tube. The dialysis by 25nM membrane
filter (Millipore, Billerica, MA, USA) for 60 min at 6 °C was
used to remove the excess salt. The DNA samples were
detected by agarose gel electrophoresis.
In the case of sandwich immunoassay, the MPs-antibodies
complex with cisplatinated DNA was twice washed by
200μL of PBS-T. The 18μl of PBS-T and 2μL of anti-
cisplatin-modified DNA antibody (1.47mg/mL) were
added to the washed MPs with removed supernatant and
the incubation was performed for 60 min during rotation
at room temperature. After that, the immunosandwich on
the MPs was twice washed with 30μL of water. Then the
MPs were resuspended in water (10μL), the 10μL of CdTe
QDs modified by HWR peptide were added and the
solution was incubated for 60 min during rotation at 40
RPM and room temperature. After the transfer of the tube
with the MPs onto a magnetic rack, the MPs were twice
washed with water (30μL). The washed MPs were resus‐
pended in 50μL of water and the fluorescence of the
coupled QDs was measured by the multifunctional
microplate reader Tecan Infinite 200 PRO 132 (Tecan,
Männendorf, Switzerland). The excitation wavelength was
360nM and the emission wavelength ranged from 390 to
850nM per 2nM steps.
2.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) of proteins
Each sample of MPs modified by anti-dsDNA antibody
was diluted four times and then mixed with protein
loading buffer (PLB) (under reducing conditions PLB with
3% mercaptoethanol) in a ratio of 2:1 and placed in the wells
of the 12.5% polyacrylamide gel (w/w) prepared from 30%
acrylamide/bis-acrylamide solution (37.5:1). Electrophore‐
sis ran in 1× tris–glycine–SDS running buffer (3.02 g of Tris,
14.4 g of glycine, 1 g of SDS and water to a final volume of
1 L) for 70 min at a voltage of 120 V in the electrophoretic
bath (Bio-Rad, Hercules, CA, USA). After that, the gels
were visualized by silver staining.
2.8 Agarose gel electrophoresis
The DNA samples eluted from the MPs were analysed via
agarose gel electrophoresis and the conditions were as
follows: 1% agarose gel (Mercury, USA) with 1 × TAE buffer
(40mM Tris, 20mM acetic acid and 1mM ethylenediamine‐
tetraacetic acid) and ethidium bromide (5μL/100mL of the
gel), 100 V and 60 min (Bio-Rad, Hercules, CA, USA). The
samples, prepared with 5% (v/v) bromophenol blue and 3%
(v/v) glycerol, were loaded into a gel in 5μL aliquots. A 100
bp DNA ladder (New England BioLabs, Ipswich, MA,
USA) within the size range from 0.1 to 1.5 kb was used to
monitor the size of the analysed fragment. The bands were
visualized via UV transilluminator at 312nM (Vilber-
Lourmat, Marne-la-Vallée Cedex, France).
The ethidium bromide fluorescence intensity was evaluat‐
ed using Carestream Molecular Software (Rochester, NY,
USA). The mean intensity and maximum intensity of the
fluorescence was quantified by software in each band and
the fluorescence of the background was deducted.
2.9 Laser ablation-inductively coupled plasma mass spectrometry
(LA-ICP-MS)
The LA-ICP-MS system, consisting of the laser ablation
(LA) system UP213 (ESI, Portland, OR, USA) and the
inductively coupled plasma mass spectrometer (ICP-MS)
Agilent 7500ce (Agilent, Santa Clara, CA, USA), was used
for quantitative determination of Pt in dot blots and in the
sandwich immunocomplexes. The LA system serves for
production of aerosol from the sample surface. Ablated
aerosol is transported by carrier gas (helium with flow of
1.0 L/min) into ICP-MS.
For calibration purposes 2μL of solution containing Pt with
concentration range 4 – 4000 ng/mL were deposited on the
membrane surface. The formed spot was ablated by
focused laser beam. The ablation was performed across the
spot with laser beam diameter of 110μm, laser beam
fluency of 5 J/cm2, repetition rate of 10 Hz and scan speed
of 200μm/s. The ICP-MS signal of Pt was monitored using
m/z = 195. The spots of the samples were analysed under
the same LA-ICP-MS parameters.
3. Results and Discussion
First, the reactivity of the anti-dsDNA and anti-cisplatin-
modified DNA antibodies was tested by dot blot. In the case
of the anti-dsDNA antibody, it was possible to detect 0.2nM
concentration (0.1 ng) of a PCR product in a spot (Figure
1A, for details see Materials and Methods section). After
determination of the spot’s intensity, a linear response in
the range of 0.2 – 162.5nM (0.1 – 100 ng) was obtained
(Figure 1B). The reactivity of the antibodies to various types
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of nucleic acids was compared in the next step. The dsDNA
(PCR product and human genomic DNA), total mRNA
(derived human leucocytes), single-stranded (ss) oligonu‐
cleotides in length of 17 and 43 bp, ds oligonucleotides in
length of 17 and 43 bp were spotted onto a membrane and
immunodetected. From Figure 1C and 1D it is obvious that
long dsDNA (e. g., PCR product and genomic DNA)
exhibited immunoreactivity with anti-dsDNA antibodies
only, while in the case of mRNA and both ss and ds
oligonucleotides, no immunoreactivity was observed.
Figure 1. The anti-dsDNA antibody characterization by dot blot. (A) The
calibration range of DNA fragment (498 bp) and (B) Determined spot
intensities. (C) The dot blot of (a) human genomic DNA, (b) λ genomic DNA
and (c) Human mRNA. (D) The dot blot of ss and ds oligonucleotides (ODN)
at different lengths, (a) ssODN 43 bp, (b) dsODN 43 bp, (c) ssODN 17 bp and
(d) dsODN 17 bp.
For verifying the immunoreactivity of the anti-cisplatinat‐
ed DNA antibody the PCR product (40.6nM) was left to
interact with different cisplatin concentrations (0 –
16.7μM). At all cisplatin concentrations the immunoreac‐
tivity with the anti-dsDNA antibody was recorded (Figure
2A), but contrary to expectations, the spot intensities varied
in dependence on cisplatin concentration. A slight increase
in the spot intensity in the range of 0 – 4.2μM concentrations
(Figure 2B inset) was observed, while at higher cisplatin
concentrations the spot’s intensities decreased markedly
(Figure 2B). This can be explained by cisplatin binding to
the DNA bulk and affecting its structure, which is essential
for immunorecognition, especially by formation of ad‐
ducts, single strand and double strand breaks, guanine
dimers and oxidative damage [26].
When the cisplatin-modified dsDNA reacted with the anti-
cisplatin-modified DNA antibody, a linear response of the
spot intensity in dependence on cisplatin concentration
was obtained (Figure 2C and Figure 2D). This indicates that
the antibody recognizes the structural changes of DNA
caused by cisplatin binding. The marked discrepancy
between the spot intensities at 8.3 and 16.7μM cisplatin
concentrations obtained for anti-dsDNA and anti-cisplatin-
modified DNA (see above) can be explained by the
destruction of dsDNA structures essential for immunore‐
cognition. The presence of Pt in the spots was verified by
LA-ICP-MS and recalculated to cisplatin equivalent. The
determined cisplatin concentration was linearly dependent
on applied cisplatin concentration with coefficient of
determination R2 = 0.98 (Figure 2E) and the determined
incorporated cisplatin amount was in the range of 44% –
69% of applied cisplatin concentrations (Figure 2E inset).
Figure 2. The cisplatinated DNA fragment detection by dot blot. To the DNA
fragment (40.6nM) different cisplatin concentrations (0 - 16.7μM) were
applied. (A) Interaction with anti-dsDNA antibody and (B) The determined
spot intensities (inset: detailed view to applied cisplatin range 0 - 4.2μM).
(C) Interaction with anti-cisplatin-modified DNA antibody and (D) The
determined spot intensities (inset: the linear range). (E) The determination
of cisplatin, incorporated within DNA, in spots by LA-ICP MS, (n = 3).
To ensure the complete saturation of the protein-G-
paramagnetic particles surface, the capacity of the beads
was tested. The amount of antibodies released from the
beads’ surface eluted by the effect of detergents and
reducing agents present in the reducing SDS-PAGE sample
buffer was determined by silver staining. The capacity of
the beads was assessed as 10μg of antibodies permg of the
beads from the increase in band intensities with size of 150,
50 and 30 kDa (corresponding to IgG whole molecule,
heavy and light chains, respectively) (Figure 3A). Usability
of the antibody-modified beads for DNA extraction from
the solution was tested by agarose electrophoresis. In
Figure 3B the result of immunoextraction of dsDNA by
beads modified with anti-dsDNA antibody is shown.
When the band intensities before and after extraction were
compared, it is obvious that when using 162.5nM concen‐
tration of the PCR product (0.38 ng/mg of MPs), 37% of the
original DNA amount was eluted (92.5 ng). To test the
extraction of cisplatinated DNA, the beads modified with
anti-dsDNA antibody were used, Figure 3C. When com‐
paring the bands’ intensity before and after extraction, it is
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obvious that when using 40.62nM DNA interacted with
8.3μM cisplatin (62.5 ng), 86% of the original DNA amount
was eluted (53.75 ng).
(A) The MPs’ binding capacity optimization. To 1mg of MPs [1] 0.25μg, [2]
0.5μg, [3] 1μg, [4] 2μg, [5] 5μg, [6] 8μg, [7] 10μg and [8] 15μg of IgG
antibodies was applied.
(B) The DNA binding by anti-dsDNA antibodies modified MPs. [1] The
DNA fragment 162.48nM as a control. [2] The eluted DNA from anti-dsDNA
antibodies modified MPs, applied DNA concentration 162.48nM. [3] The
eluted DNA from anti-dsDNA antibodies modified MPs after dialysis.
(C) The cisplatinated DNA binding by anti-dsDNA-modified MPs. [1] The
DNA fragment 40.62nM as a control. [2] The eluted DNA from anti-dsDNA
antibodies modified MPs, applied DNA concentration was 81.24nM with
8.33μM cisplatin. [3] The eluted cisplatinated DNA from anti-dsDNA
antibodies modified MPs after dialysis.
Figure 3. The characterization of MPs coated with antibodies evaluated by
gel electrophoresis.
On the basis of the obtained results, a bead-based sensor
for cisplatinated DNA was proposed. The construction of
a sensor composed from sandwich construction bead –
anti-dsDNA antibody – cisplatinated DNA – QD-labelled
anti-cisplatin-modified DNA antibody (Figure 4A). The
process of antibodies labelling by QDs was adopted from
[22]. 40.62nM (125 ng) lambda DNA was interacted with 0,
8.3 and 16.7μM cisplatin and consequently used for testing
of the sensor. Compared to DNA without cisplatin, at all
applied cisplatin concentration a 5.3- or 6.6-fold increase in
fluorescence was observed (Figure 4B). The fluorescence
signal of the sensor without DNA was undetectable.
The concentration of Pt in eluted DNA was determined by
LA-ICP-MS and recalculated to cisplatin equivalent (Figure
4C). When compared with the applied and eluted cisplatin,
in the eluted DNA solution 32% of applied cisplatin was
present for 8.3μM cisplatin and 42% for 16.7μM cisplatin.
This confirms that the recorded fluorescent signal is caused
































































Figure 4. (A) The scheme of sandwich immunoassay on MPs where [1] the
anti-dsDNA antibody and [2] anti-cisplatin-modified DNA antibody
labelled by QDs. (B) The fluorescence intensity of QDs coupled to anti-
cisplatin-modified DNA antibodies, which labelled the cisplatinated DNA
bound to MPs modified by anti-dsDNA antibodies. (C) The cisplatin
concentration determined by LA-ICP-MS after elution from MPs. Inset:
calculated percentage of cisplatin incorporated in DNA that was immuno‐
separated.
The proposed procedure will be tested for quantification of
DNA adducts in cisplatin-treated tumour cells [27]. After
using different antibodies, which recognize either particu‐
lar type of DNA damage (DNA breaks, doxorubicin
modifications, short DNA fragments, etc.), this procedure
can be easily modified for concrete application, for exam‐
ple, determination of free DNA in autoimmune diseases,
such as systemic lupus erythematosus or circulating
tumour DNA [28]. In the 1970s, tumour imaging utilizing
radioiodinated DNA for tumour imaging was published
[29]. After cisplatin therapy, the proposed sensor could be
usable for theranostics (double imaging using QDs and
paramagnetic particles [30]) and hyperthermia (paramag‐
netic particles) [31].
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Among the analytical approaches currently used for
measuring DNA adducts, we can include 32P-post-labeling,
immunoassay using antibodies against modified DNA,
conventional mass spectrometry (MS) and accelerator MS
[32]. Immunoassays are powerful tools for the analysis of
DNA adducts. They have provided sufficient sensitivity
and selectivity for quantification of clinically relevant low
levels of DNA modifications [33]. However, immunoassays
do not provide structural information about adducts. The
high sensitivity of the 32P-post-labeling is most frequently
used for DNA-adduct detection [34]. However, it suffers
from several drawbacks, including the need for reference
standards and the inability to characterize unknown
adducts. Moreover, it is susceptible to false positives or
false negatives, it utilizes radioactivity and numerous
sample pretreatment steps have to be conducted to ensure
that adducts are well purified and isolated from non-
adducted DNA fragments. Thus the 32P-post-labeling
procedure is still very laborious; the time-span for analysis
is of the order of days. One important limitation of this
method is the variable yield of the different enzymatic
reactions (necessary for preparation of 32P-labeled species),
which complicates absolute quantitative determination of
DNA adducts [32]. Significant advances have been made in
developing MS-based approaches with improved sensitiv‐
ity and versatility, to provide new insights and more
conclusive information due to the high specificity inherent
in the MS technique. It is therefore now possible to charac‐
terize and to determine platinated DNA adducts by MS-
based methodologies with sensitivity comparable to that of
32P-post-labeling or immunoassays [35].
Paramagnetic particle-based immunoassay requires less
time and lower sample amount to perform the analysis and
labelling with nanoparticles offers the possibility of
multianalyte determination [23, 36].
4. Conclusions
We suggested an easy magnetic separation-based assay for
DNA quantification, which is usable for quantification of
DNA lesions in cells treated with cytostatics. Using
antibodies, which recognize either particular type of DNA
damage (DNA breaks, doxorubicin modifications, short
DNA fragments, etc.), allows easy modification of this
procedure for concrete application. After cisplatin therapy,
the proposed sensor could be usable for theranostics
(double imaging using QDs and paramagnetic particles)
and hyperthermia (paramagnetic particles).
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